Jerusalem Pharmaceutical Co (XPAE:JPH) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAE:JPH Jerusalem Pharmaceutical Co XPAE:JPH
82 GF Score
Price $3.57
GF Value $2.41
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jerusalem Pharmaceutical Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Jerusalem Pharmaceutical Co Valuation Rank Related Terms

XPAE:JPH
82GF Score
Jerusalem Pharmaceutical Co XPAE:JPH
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jerusalem Pharmaceutical Co (XPAE:JPH) Overvalued in 2026?

Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co stock appears to be overvalued. The current stock price of $3.57 is trading 48.1% above its estimated GF Value™ of $2.41. GuruFocus considers Jerusalem Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for XPAE:JPH:

  • Valuation Rank:
  • GF Value™: $2.41 vs. price of $3.57 (48.1% above fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the XPAE:JPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jerusalem Pharmaceutical Co Business Description

Address Nablus Street, Jerusalem Pharmaceuticals Company Buliding, Al Bireh Industrial Zone, Al Bireh, PSE, 3570
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
82GF Score

Get the complete analysis for XPAE:JPH

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.57
Price
$2.41
GF Value